Beam Therapeutics Inc. (BEAM, Financial) experienced a significant stock price increase of 5.13% recently, trading at $23.04 per share. The trading volume reached 295,149 shares, with a turnover rate of 0.36% and a volatility amplitude of 4.31%.
In its latest financial report, Beam Therapeutics reported revenue of $11.77 million and a net loss of $91.05 million, equating to an earnings per share of -$1.11. The gross profit was $6.20 million, and the price-to-earnings (P/E) ratio stands at -14.20.
Regarding analyst ratings, out of 18 analysts, 50% recommend buying the stock, while the other 50% suggest holding it. No analysts recommended selling.
The biotechnology sector, where Beam Therapeutics operates, saw an overall increase of 0.59%. Notable performances from related stocks include Revolution Medicines Inc and Athira Pharma, with high activity observed in stocks like Theriva Biologics and Ensysce Biosciences, featuring turnover rates of 3504.60% and 892.50% respectively.
Beam Therapeutics is a biotechnology company leveraging its base editing technology to develop gene therapies. This technology enables targeted editing of individual bases in the genome without causing double-strand breaks in DNA. Their project pipeline includes BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
